TY - JOUR
T1 - A European survey of management approaches in chronic urticaria in children
T2 - EAACI pediatric urticaria taskforce
AU - Tsabouri, Sophia
AU - Arasi, Stefania
AU - Beken, Burcin
AU - Church, Martin K.
AU - Alvaro-Lozano, Montserrat
AU - Caffarelli, Carlo
AU - Flohr, Carsten
AU - Janmohamed, Sherief R.
AU - Konstantinou, George N.
AU - Lau, Susanne
AU - Lefevre, Sebastien
AU - Mortz, Charlotte G.
AU - Pajno, Giovanni
AU - Pite, Helena
AU - Rutkowski, Krzysztof
AU - Staubach, Petra
AU - Van der Poel, Lauri Ann
AU - Zuberbier, Torsten
AU - Leslie, Tabi A.
N1 - Funding Information:
None of the authors perceived any fee for the present work. The online platform was supported by an EAACI grant
Publisher Copyright:
© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2022/1
Y1 - 2022/1
N2 - Background: Although well described in adults, there are scarce and heterogeneous data on the diagnosis and management of chronic urticaria (CU) in children (0–18 years) throughout Europe. Our aim was to explore country differences and identify the extent to which the EAACI/GA²LEN/EDF/WAO guideline recommendations for pediatric urticaria are implemented. Methods: The EAACI Task Force for pediatric CU disseminated an online clinical survey among EAACI pediatric section members. Members were asked to answer 35 multiple choice questions on current practices in their respective centers. Results: The survey was sent to 2,773 physicians of whom 358 (13.8%) responded, mainly pediatric allergists (80%) and pediatricians (49.7%), working in 69 countries. For diagnosis, Southern European countries used significantly more routine tests (eg, autoimmune testing, allergological tests, and parasitic investigation) than Northern European countries. Most respondents (60.3%) used a 2nd-generation antihistamine as first-line treatment of whom 64.8% updosed as a second line. Omalizumab was used as a second-line treatment by 1.7% and third line by 20.7% of respondents. Most clinicians (65%) follow EAACI/WAO/GA2LEN/EDF guidelines when diagnosing CU, and only 7.3% follow no specific guidelines. Some clinicians prefer to follow national guidelines (18.4%, mainly Northern European) or the AAAAI practice parameter (1.7%). Conclusions: Even though most members of the Pediatric Section of EAACI are familiar with the EAACI/WAO/GA2LEN/EDF guidelines, a significant number do not follow them. Also, the large variation in diagnosis and treatment strengthens the need to re-evaluate, update, and standardize guidelines on the diagnosis and management of CU in children.
AB - Background: Although well described in adults, there are scarce and heterogeneous data on the diagnosis and management of chronic urticaria (CU) in children (0–18 years) throughout Europe. Our aim was to explore country differences and identify the extent to which the EAACI/GA²LEN/EDF/WAO guideline recommendations for pediatric urticaria are implemented. Methods: The EAACI Task Force for pediatric CU disseminated an online clinical survey among EAACI pediatric section members. Members were asked to answer 35 multiple choice questions on current practices in their respective centers. Results: The survey was sent to 2,773 physicians of whom 358 (13.8%) responded, mainly pediatric allergists (80%) and pediatricians (49.7%), working in 69 countries. For diagnosis, Southern European countries used significantly more routine tests (eg, autoimmune testing, allergological tests, and parasitic investigation) than Northern European countries. Most respondents (60.3%) used a 2nd-generation antihistamine as first-line treatment of whom 64.8% updosed as a second line. Omalizumab was used as a second-line treatment by 1.7% and third line by 20.7% of respondents. Most clinicians (65%) follow EAACI/WAO/GA2LEN/EDF guidelines when diagnosing CU, and only 7.3% follow no specific guidelines. Some clinicians prefer to follow national guidelines (18.4%, mainly Northern European) or the AAAAI practice parameter (1.7%). Conclusions: Even though most members of the Pediatric Section of EAACI are familiar with the EAACI/WAO/GA2LEN/EDF guidelines, a significant number do not follow them. Also, the large variation in diagnosis and treatment strengthens the need to re-evaluate, update, and standardize guidelines on the diagnosis and management of CU in children.
UR - http://www.scopus.com/inward/record.url?scp=85116944208&partnerID=8YFLogxK
U2 - 10.1111/pai.13674
DO - 10.1111/pai.13674
M3 - Article
C2 - 34601755
AN - SCOPUS:85116944208
SN - 0905-6157
VL - 33
JO - Pediatric Allergy And Immunology
JF - Pediatric Allergy And Immunology
IS - 1
M1 - e13674
ER -